Gene · 9100
Papers1,422
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,422
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of a novel USP10 inhibitor with improved aqueous solubility for the treatment of hepatocellular carcinoma. | Bioorg Chem | 2026 | 41443012 | PubTator, text mining | PubMed |
| Dual faces of USP10 in breast cancer: Oncogenic driver, tumor suppressor, and emerging therapeutic target. | Biomed Pharmacother | 2026 | 41418667 | PubTator, text mining | PubMed |
| USP10 promotes cell proliferation and gemcitabine resistance in pancreatic cancer by the regulation of IGF2BP3-STEAP3. | Oncogene | 2026 | 41381842 | PubTator, text mining | PubMed |
| USP10 in Neurological Disorders: Mechanistic Insights and Emerging Therapeutic Strategies. | Ann N Y Acad Sci | 2026 | 41284210 | PubTator, text mining | PubMed |
| PRDM15 promotes colorectal carcinogenesis by transcriptionally repressing USP10 to destabilize p53. | Biochim Biophys Acta Mol Basis Dis | 2026 | 41175978 | PubTator, text mining | PubMed |
| Stabilization of VDAC1 by USP10 facilitates radioresistance and metastasis in nasopharyngeal carcinoma via MTOR-dependent autophagy pathway: an experimental study. | Int J Surg | 2026 | 41147769 | PubTator, text mining | PubMed |
| piR-61298 promotes colorectal cancer progression through destabilizing p53 by interacting with USP10. | J Biomed Res | 2026 | 40789668 | PubTator, text mining | PubMed |
| A Ubiquitination-Related Gene Prognostic Signature and the Oncogenic Role of RNF149 in Nasopharyngeal Carcinoma: scRNAseq- Based Bioinformatics and Experimental Validation. | Curr Med Chem | 2026 | 40574357 | PubTator, text mining | PubMed |
| BMP9 alleviates iron accumulation-induced osteoporosis via the USP10/FOXO1/GPX4 axis. | J Adv Res | 2026 | 40068762 | PubTator, text mining | PubMed |
| USP10-VDAC1 in NPC: mechanism without translation? -- Letter to the Editor. | Int J Surg | 2025 | 41376495 | PubTator, text mining | PubMed |
| Changing the channel: USP10 unlocks a chaperone-mediated autophagy pathway for NaV1.5. | Cardiovasc Res | 2025 | 41288585 | PubTator, text mining | PubMed |
| Arsenic promotes ROS-mediated malignant transformation of bronchial epithelial cells by specifically downregulating TXNL1 expression. | Commun Biol | 2025 | 41275040 | PubTator, text mining | PubMed |
| Melittin inhibits NSCLC metastasis by targeting USP10 and promoting RNF20-mediated ubiquitination and degradation of PSMA7. | J Transl Med | 2025 | 41254650 | PubTator, text mining | PubMed |
| AEG-1 on cancer drug resistance: From molecular insights to therapeutic challenges. | Adv Cancer Res | 2025 | 41242859 | PubTator, text mining | PubMed |
| Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer. | Sci Adv | 2025 | 41071892 | PubTator, text mining | PubMed |
| MUC1 drives ferroptosis resistance in ICC via Src-mediated FSP1 deubiquitination and myristoylation. | Clin Transl Med | 2025 | 41068561 | PubTator, text mining | PubMed |
| ERβ/circAHNAK Axis Inhibits USP10-FMR1 Deubiquitination to Prevent m⁶A-Mediated ADAM17 Decay and Promote Angiogenesis in Clear Cell Renal Cell Carcinoma. | Adv Sci (Weinh) | 2025 | 41058008 | PubTator, text mining | PubMed |
| ARL3 Enhances ERα Stability via USP10 Deubiquitination to Promote Endocrine Resistance and Drive Mitochondrial Metabolic Reprogramming in HR+ Breast Cancer. | Adv Sci (Weinh) | 2025 | 41047477 | PubTator, text mining | PubMed |
| SETD5 in glioma cells conferred TRAIL resistance induction. | Sci Rep | 2025 | 41023048 | PubTator, text mining | PubMed |
| USP10/GSK3β-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer. | J Clin Invest | 2025 | 40991650 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9100/papers?page=4